Higher-risk MDS: An update on emerging novel agents

touchTALKS for touchONCOLOGY

Listen to a leading expert in higher-risk myelodysplastic neoplasms (HR-MDS) discuss the impact that emerging treatment options may have on clinical practice. Dr David Sallman covers the latest updates to the classification of HR-MDS, the mode of action of emerging therapeutic agents and the most recent clinical evidence on their efficacy and safety.

The expert:

• Dr David Sallman, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/hr-mds-emerging-treatments/